The GH/IGF-1 system in critical illness

Itoro E. Elijah, Ludwik K. Branski, Celeste C. Finnerty, David N. Herndon

Research output: Contribution to journalReview articlepeer-review

74 Scopus citations


The Growth Hormone and Insulin-like Growth Factor-1 (IGF-1) axis plays a pivotal role in critical illness, with a derangement leading to profound changes in metabolism. Protein wasting with skeletal muscle loss, delayed wound healing, and impaired recovery of organ systems are some of the most feared consequences. The use of human recombinant Growth Hormone (rhGH) and Insulin-like Growth Factor-1 (IGF-1) - alone and in combination - has been studied extensively in preclinical and clinical trials. This article reviews the current knowlegde and clinical practice of the use of rhGh and IGF-1 in critically ill patients, with a special focus on the trauma and burns patient population.

Original languageEnglish (US)
Pages (from-to)759-767
Number of pages9
JournalBest Practice and Research: Clinical Endocrinology and Metabolism
Issue number5
StatePublished - Oct 2011


  • IGFBP-3
  • anabolic therapy
  • burns
  • gut atrophy
  • hepatic acute care response
  • hypermetabolism
  • mortality
  • nutrition
  • protein wasting
  • trauma

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology


Dive into the research topics of 'The GH/IGF-1 system in critical illness'. Together they form a unique fingerprint.

Cite this